Well-characterized syngeneic murine models to evaluate the efficacy of novel immunotherapies

Syngeneic Murine Models In vivo Services for Immuno-Oncology

A 10 year experience in syngeneic murine models

  • Murine models with a complete immune system 
  • Subcutaneous or orthotopic inoculation of tumor cells
  • Validated models known for their response to standard treatments and immune response profile
syngeneic tumor models in vivo efficacy studies CRO

Custom in vivo evaluation of immunotherapy efficacy

  • We adapt administration route & schedule to your need
  • Weekly reports about anti-tumor response: tumor size, body weight, survival assessed 3 times per week
  • Flexible collection of liquid and solid samples
murine syngeneic cancer models assess immunotherapies

Analysis of tumor-microenvironment & peripheral markers

  • Monitoring anti-cancer immune response throughout the study, with satellite mice, bleedings, intra-tumoral biopsies, or tumor microdialysis
  • In-house platform for multiplexed immunophenotyping by flow cytometry, digital histopathology, digital spatial profiling (DSP), proteomics, …

Why working with Explicyte?

in Immuno-Oncology

  • 150+ in vivo studies already performed
  • 25+ papers in high-impact factor journals
  • 10 year-experience in custom experimental & analytical strategies

A flexible

  • A top-level scientist dedicated to each study direction from experimental plan to final report
  • Weekly reports to provide regular updates & adapt experimental strategy
  • Comprehensive analytical platform to decipher anti-tumor response

Your contacts

explicyte team 2024

Talk to our team !

Paul Marteau, PharmD (preclinical study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (translational study director)

Tell us about your project !

    Select department:

    Syngeneic Tumor Models for the In Vivo Assessment Cancer Immunotherapies I Preclinical CRO services in Immuno-Oncology

    Over the past 10 years,Explicyte Immuno-Oncology developed a range of syngeneic mouse tumor models for the in vivo evaluation of novel cancer immunotherapies. Our models are based on the subcutaneous or orthotopic implantation of murine tumor cells in immuno-competent mouse. All our models were validated using standard treatments, such as immune checkpoint inhibitors or reference chemotherapies. Anti-tumor efficacy and immune markers are well-characterized in such models.

    WordPress Lightbox